Two New Studies On Classical Psychedelics: Grading Ketamine’s Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce
Health Canada Oks Clinical-Grade MDMA Export To UK
Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its manufacturing partners received a Health Canada export permit for no less than 300 grams of proprietary MDMA LaNeo.
EXCLUSIVE: Next-Generation Psychedelics, MEAI – How And Why, An Israeli Scientist Explains
(This is part two of a four-part series)
Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee.
New, Standardized Magic Mushroom Microdosing Capsules By Red Light Holland And Partner CCrest Labs
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction
Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is set to commence this February.
Psychedelics Travel: Clinical-Grade Magic Mushrooms Extract Exported From Southern Africa To UK
Lifesciences psychedelics biotech Psyence Group Inc. (OTCQB: PSYGF) recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in Southern Africa to its Contract Development & Manufacturing Organization (CDMO) partner in the UK.
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
(Part one of a four-part series)
Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights.
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.